Bottom line
PHSYX vs ETHSX: the short answer
PHSYX (Putnam Global Health Care Fund) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 71% by weight.
But PHSYX is far broader, holding 115 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
PHSYX is cheaper at 0.79% vs 1.18% — a difference of $39 a year per $10,000 invested.
Over five years, PHSYX returned +8.1% a year vs +5.3% for ETHSX.
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
PHSYX vs ETHSX side by side
| PHSYX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.79% | 1.18% |
| Annual cost per $10k | $79 | $118 |
| 10-yr cost on $10k (prospectus) | $978 | $1,911 |
| Max front load | 0% | 5.25% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +1.5% | −1.9% |
| 5-yr return (annualized) | +8.1% | +5.3% |
| 10-yr return (annualized) | +7.8% | +6.4% |
| Best quarter | — | +14.2% |
| Worst quarter | — | −12.1% |
| Net assets (fund) | $1.5B | $757.9M |
| Number of holdings | 115 | 42 |
| Portfolio turnover | 67% | 3% |
| Returns as of | Dec 31, 2024 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
16 of PHSYX's top 25 holdings also appear in ETHSX's top 25.
| Holding | PHSYX | ETHSX |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 12.47% |
| Johnson & Johnson | 8.46% | 6.45% |
| UnitedHealth Group, Inc. | 6.93% | 5.49% |
| AbbVie, Inc. | 6.05% | 6.46% |
| Novartis AG | 5.13% | 1.65% |
| Merck & Co., Inc. | 4.88% | 5.08% |
| AstraZeneca plc | 4.67% | 6.24% |
| Thermo Fisher Scientific, Inc. | 4.50% | 2.79% |
| Intuitive Surgical, Inc. | 4.04% | 2.72% |
| Sanofi SA | 3.23% | 2.95% |
| Roche Holding AG | 2.79% | 5.44% |
| Gilead Sciences, Inc. | 2.63% | 3.34% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 3.38% |
| Novo Nordisk A/S | 1.90% | 1.71% |
| Boston Scientific Corp. | 1.80% | 2.18% |
Source: SEC Form N-PORT
PHSYX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between PHSYX and ETHSX?
Which is cheaper, PHSYX or ETHSX?
Should I own both PHSYX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.